Related Experiment Video
Updated: Jun 14, 2025
08:36
The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
Published on: July 28, 2022
3.7K
Digital Therapeutics for Cognitive Impairment: Exploring Innovations, Challenges, and Future Prospects
Grace Yuange Zang1,2, Keqin Rao2, Jing Wu3
1Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States.
Journal of Medical Internet Research
|June 12, 2025
Summary
Digital therapeutics offer new ways to manage cognitive impairment, but integration faces challenges. Addressing these through collaboration and user-centered design is key for future success in cognitive health.
Area of Science:
- Cognitive Neuroscience
- Digital Health Technology
Background:
- Advancements in cognitive neuroscience and digital technology are driving the adoption of digital therapeutics for cognitive impairment.
- Digital therapeutics are increasingly used for assessment, intervention, management, and monitoring of cognitive disorders.
Purpose of the Study:
- To explore innovative applications of digital therapeutics for cognitive disorders (CDTx).
- To identify and analyze key challenges hindering the widespread clinical integration of CDTx.
- To offer strategic recommendations for the future development and implementation of CDTx.
Main Methods:
- Viewpoint analysis of current literature and expert perspectives.
- Examination of CDTx definition and multistakeholder collaboration requirements.
- Exploration of challenges from clinical, policy, user, ethical, and technical viewpoints.
Main Results:
- Digital therapeutics show promise in various aspects of cognitive disorder management.
- Significant challenges exist in clinical practice, policy, user adoption, ethics, privacy, and data integration.
- Multistakeholder collaboration and user-centered design are crucial for CDTx success.
Conclusions:
- Strategic recommendations focus on collaboration, user-centered design, and AI integration.
- Addressing identified challenges is essential for enhancing the scalability and sustainability of CDTx.
- Future prospects of CDTx depend on overcoming integration barriers and leveraging emerging technologies.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
108
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
108
01:29Issues And Trends In Healthcare Delivery System
5.6K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
5.6K
01:30Dementia
107
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
107
01:28Drug Therapy
40
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
40
01:30Cognitive Development During Adulthood
68
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
68
01:26Alzheimer's Disease: Overview
452
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
452